Press Releases Karolinska Development AB

Equities

KDEV

SE0002190926

Market Closed - Nasdaq Stockholm Other stock markets 11:21:17 2024-04-26 am EDT			5-day change	1st Jan Change
1.57 ^SEK	+3.43%		+3.43%	-7.54%

Apr. 26	Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Interim Report - January-March 2024	Apr. 26	GL
Notice of Annual General Meeting in Karolinska Development AB (publ)	Apr. 16	GL
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	Mar. 22	PU
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	Mar. 22	GL
Karolinska Development Annual Report 2023 published	Mar. 22	GL
Karolinska Development Annual Report 2023 published	Mar. 22	AQ
Karolinska Development : portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million	Mar. 14	PU
Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million	Mar. 14	GL
Karolinska Development : portfolio company Biosergen publishes prospectus due to rights issue of units	Mar. 14	PU
Karolinska Development’s portfolio company Biosergen publishes prospectus due to rights issue of units	Mar. 14	GL
Karolinska Development : portfolio company Umecrine Cognition presents preclinical Parkinson's data on golexanolone at AD/PD	Mar. 06	PU
Karolinska Development’s portfolio company Umecrine Cognition presents preclinical Parkinson’s data on golexanolone at AD/PD	Mar. 06	GL
Year-end Report - January-December 2023	Feb. 16	GL
Karolinska Development’s portfolio company AnaCardio secures SEK 50 million as part of its Series A investment round	Jan. 17	GL
Karolinska Development's portfolio company OssDsign reports exceptional clinical data for its nanosynthetic bone graft product	Jan. 09	GL
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates	Dec. 06	GL
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration	Dec. 04	GL
Karolinska Development’s portfolio company PharmNovo´s drug candidate PN6047 in a NIDA funded collaboration	Dec. 04	AQ
Karolinska Development’s portfolio company Umecrine Cognition presents positive effects of golexanolone in a preclinical model of cholestasis	Nov. 28	GL
Karolinska Development’s portfolio company Umecrine Cognition raises additional funding for the clinical development of golexanolone	Nov. 17	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Karolinska Development AB

Equities

KDEV

SE0002190926

Press Releases

Filters